# Axatilimab + CAR-T for High-Risk Lymphoma

> **NCT07638982** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Northside Hospital, Inc.** · enrollment: 29 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)
- Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma (HGBCL)
- High-Grade B-Cell Lymphoma, Nos
- PMBCL
- Follicular Grade 3 Lymphoma

## Interventions

- **DRUG:** Axatilimab

## Key facts

- **NCT ID:** NCT07638982
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638982, "Axatilimab + CAR-T for High-Risk Lymphoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*